 | | Vol. 11.29 – 27 July, 2022 |
| |
|
|
| Cell fusion between glioma stem cells and mesenchymal stem cells was found by the method of Cre-LoxP switch gene and RFP/GFP dual-color fluorescence tracing.
[ACS Applied Materials & interfaces] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Patient-derived organoid models demonstrated that KS10076 efficiently represses cancer cells with active KRAS, and fluorouracil resistance, which suggested clinical advantages.
[Cell Reports] |
|
|
|
| The abundance of hypoxic and normoxic CSCs was analyzed in primary colorectal cancer tumors. It was found that the proportion of normoxic CSCs was positively associated with tumor stage.
[Cell Death & Disease] |
|
|
|
| Investigators identified the tumor suppressor p53 as a key regulator that transcriptionally repressed the expression of SET in both normal and cancer cells.
[Science China Life Sciences] |
|
|
|
| The authors reported that a HECT-like E3 ligase, UBE3D, participated in stabilizing CPFS73 protein by preventing its ubiquitin-mediated degradation by the proteasome.
[iScience] |
|
|
|
| Based on 3D organoid culture of hepatocellular carcinoma-derived cell lines and AAV8-based protein overexpression in the mouse liver, investigators showed that activity modulation of isoform δ of phosphoinositide 3-kinase (PI3Kδ) controls differentiation and discriminates between stemness.
[Communications Biology] |
|
|
|
| LpMab-2 (Lp2)-chimeric antigen receptor (CAR) transduced T cells (Lp2-CAR-T) specifically targeted podoplanin (PDPN)-expressing glioma cells, while sparing the PDPN-expressing normal cells. Lp2-CAR-T also killed patient-derived glioma stem cells, demonstrating its clinical potential against glioblastoma.
[Molecular Therapy-Oncolytics] |
|
|
|
| Investigators respectively detected the in vitro and in vivo tumor-suppression efficacy of chimeric antigen receptor (CAR) T cells through the CCK-8 assays and the hepatocellular carcinoma xenograft mice models.
[BMC Cancer] |
|
|
|
| The authors described an adapted proximity ligation assay protocol for the assessment of galectin-1-HOXA5 interaction in brain tumor stem cells.
[STAR Protocols] |
|  |
|
|
|
| | Investigators discuss prostate cancer (PCa) from the perspective of an abnormal organ with increasingly deregulated differentiation, and discuss the role of androgen receptor signaling during PCa progression<.br/>[Essays in Biochemistry] |
|
|
|
|
| QBiotics Group Limited has been granted approval of its Investigational New Drug application by the US FDA for lead oncology molecule, tigilanol tiglate.
[QBiotics Group Limited] |
|
|
|
|
Kite announced that the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus® for the treatment of adult patients 26 years of age and above with r/r ALL.
[Gilead Sciences, Inc.] |
| |
|
|
| Aug 7 – 12, 2022
Saxtons River, Vermont, United States |
|
|
|
|
|
| | Sanford Research – Sioux Falls, South Dakota, United States |
|
|
|
| | Mayo Clinic – Scottsdale, Arizona, United States |
|
|
|
| | Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
| | Boehringer Ingelheim – Vienna, Austria |
|
|
|
| | The Chinese University of Hong Kong – Hong Kong, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
